📰 ReutersReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 09:01:25时区推断·⟳ 抓取 09:04:21·⚡ 决策 07-29 09:05:32 +1m11s·90.4 天前
CSL将启动Horizon 2免疫球蛋白新工艺临床试验以提高同等血浆产出
Horizon 2属于提高免疫球蛋白生产良率的工艺改进，对CSL核心血浆制品长期利润率有正面含义。
📄 原文Reuters↗ 原文
Australian biotechnology firm CSL (CSL.AX) said on Wednesday it would start clinical trials to support regulatory appr…
不做 CSL（CSL.AU）
工艺临床试验要到2027年中才启动，短线商业化和利润增量无法量化；且CSL.AX已在本事件中最高上涨7.7%，隔夜追多没有足够edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Reuters报道CSL将启动Horizon 2免疫球蛋白新工艺临床试验，并披露股价盘中已最高上涨7.7%。市场反应:CSL.AX盘中最高涨7.7%，为S&P/ASX 200成分股中表现最强之一。
- CSL产品管线列示Horizon 2 Ig Yield项目，定位为通过新技术优化流程、提高Ig良率。
关键理由
- Horizon 2属于提高免疫球蛋白生产良率的工艺改进，对CSL核心血浆制品长期利润率有正面含义。
- 但临床工作预计到2027年中才开始，当前只是为监管批准做试验准备，短线收入和利润增量无法落地。
- 原文已显示CSL（CSL.AX）当日最高上涨7.7%，事件到达时主要价格反应已经发生。
主要风险
- 临床和监管审批仍需验证安全性、有效性及工艺可比性，商业化时间较远。
- CSL为大市值血制品龙头，单一工艺试验启动且未披露量化增量，难以支撑隔夜追多。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
近期市场观点仍提示CSL短期盈利压力和中国增长放缓，Horizon 2良率改善更像中长期利润率反证而非短线催化。
检索:CSL short term earnings decline China revenue slowing Horizon 2 yield improvement 2028 2030 原文 ↗
原文全文
展开原文 · 1,114 字
Australian biotechnology firm CSL (CSL.AX) said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma.
Here are the details:
CSL said the studies would test the safety and efficacy of immunoglobulin produced with its proprietary Horizon 2 technology after talks with the U.S. Food and Drug Administration and the European Medicines Agency.
The company said Horizon 2 is a patented process that increases yield, potentially improving manufacturing efficiency for one of its key products.
Clinical work is expected to begin in mid-2027 using material produced at CSL's Broadmeadows facility in Australia.
In November, the Melbourne-based firm said it would invest $1.5 billion in the United States to manufacture plasma-derived therapies, to expand its footprint over the next five years.
Shares of the company rose as much as 7.7% to A$128.670, their highest since April 29. The stock was the top gainer on the benchmark S&P/ASX 200 index (.AXJO), which was up 1.1%.
Here are the details:
CSL said the studies would test the safety and efficacy of immunoglobulin produced with its proprietary Horizon 2 technology after talks with the U.S. Food and Drug Administration and the European Medicines Agency.
The company said Horizon 2 is a patented process that increases yield, potentially improving manufacturing efficiency for one of its key products.
Clinical work is expected to begin in mid-2027 using material produced at CSL's Broadmeadows facility in Australia.
In November, the Melbourne-based firm said it would invest $1.5 billion in the United States to manufacture plasma-derived therapies, to expand its footprint over the next five years.
Shares of the company rose as much as 7.7% to A$128.670, their highest since April 29. The stock was the top gainer on the benchmark S&P/ASX 200 index (.AXJO), which was up 1.1%.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。